OverviewSuggest Edit

Unum Therapeutics uses proprietary T-cell engineering technology in combination with tumor-targeting antibodies to activate the body’s own immune system to fight cancer. Unum’s lead program, based on its Antibody-Coupled T-cell Receptor (ACTR) technology, is expected to enter Phase I clinical testing in the coming months to assess safety and efficacy. Unum is seeking partners interested in using the ACTR technology to arm proprietary tumor-specific antibodies with a T-cell to improve their therapeutic potential. The company is headquartered in Cambridge, MA.
TypePublic
Founded2014
HQCambridge, MA, US
Websiteunumrx.com

Latest Updates

Employees (est.) (Apr 2018)56(-3%)
Revenue (FY, 2017)$8.4 M(+32%)
Share Price (Jan 2021)$9.1(-5%)
Cybersecurity ratingAMore

Key People/Management at UNUM Therapeutics

John Green

John Green

Chief Financial Officer
Erin Schellhammer

Erin Schellhammer

Chief People Officer
Peter Harwin

Peter Harwin

Director
Chris Cain

Chris Cain

Director
Karen Ferrante

Karen Ferrante

Director
Arlene M. Morris

Arlene M. Morris

Director
Show more

UNUM Therapeutics Office Locations

UNUM Therapeutics has an office in Cambridge
Cambridge, MA, US (HQ)
200 Cambridgepark Dr #3100
Show all (1)

UNUM Therapeutics Financials and Metrics

UNUM Therapeutics Revenue

UNUM Therapeutics's revenue was reported to be $8.36 m in FY, 2017 which is a 31.5% increase from the previous period.
USD

Revenue (FY, 2017)

8.4m

Revenue growth (FY, 2016 - FY, 2017), %

31.5%

Net income (FY, 2017)

(25.5m)

EBIT (FY, 2017)

(26.2m)

Market capitalization (28-Jan-2021)

73.2m

Closing stock price (28-Jan-2021)

9.1

Cash (31-Dec-2017)

28.3m
UNUM Therapeutics's current market capitalization is $73.2 m.
USDFY, 2015FY, 2016FY, 2017

Revenue

3.0m6.4m8.4m

Revenue growth, %

113%32%

General and administrative expense

2.7m3.4m4.7m

R&D expense

6.9m22.0m29.8m
USDFY, 2016FY, 2017

Cash

41.3m28.3m

Accounts Receivable

928.0k830.0k

Prepaid Expenses

296.0k513.0k

Current Assets

69.7m42.4m
USDFY, 2015FY, 2016FY, 2017

Net Income

(6.6m)(18.1m)(25.5m)

Depreciation and Amortization

179.0k830.0k1.2m

Accounts Payable

705.0k389.0k(31.0k)

Cash From Operating Activities

17.7m(18.6m)(25.8m)
Show all financial metrics

UNUM Therapeutics Operating Metrics

Mar, 2018

Phase I Trials Products

3

Pre-Clinical Phase Products

1
Show all operating metrics

UNUM Therapeutics Cybersecurity Score

Cybersecurity ratingPremium dataset

A

90/100

SecurityScorecard logo

UNUM Therapeutics Environment, Social & Governance (ESG) Ratings

CSRHub ESG ratingPremium dataset

30-39

out of 100

CSRHub logo

UNUM Therapeutics Online and Social Media Presence

Embed Graph

UNUM Therapeutics News and Updates

Thinking about buying stock in Unum Therapeutics, Omeros Corp, Workhorse Group, Norwegian Cruise Line, or Delta Air Lines?

NEW YORK, Aug. 31, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for UMRX, OMER, WKHS, NCLH, and DAL. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link....

Thinking about buying stock in Hudson Ltd, Unum Therapeutics, GrowGeneration, TOP Ships, or Norwegian Cruise Line?

NEW YORK, Aug. 19, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for HUD, UMRX, GRWG, TOPS, and NCLH. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link....

Thinking about buying stock in Unum Therapeutics, Nokia, Amneal Pharmaceuticals, Aytu Bioscience, or Niu Technologies?

NEW YORK, July 10, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for UMRX, NOK, AMRX, AYTU, and NIU. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link....

Thinking about buying stock in Unum Therapeutics, Diffusion Pharmaceuticals, Sunrun Inc, Delta Air Lines, or Hertz Global Holdings?

NEW YORK, July 7, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for UMRX, DFFN, RUN, DAL, and HTZ. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link....

Unum Therapeutics Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Corporate Updates

CAMBRIDGE, Mass., March 26, 2020 (GLOBE NEWSWIRE) -- Unum Therapeutics Inc. (NASDAQ: UMRX), a biopharmaceutical company focused on developing curative cell therapies for solid tumors, today announced financial results for the fourth quarter and full year ended December 31, 2019, and provided corpo…

Unum Therapeutics Announces Common Stock Purchase Agreement for up to $25 Million with Lincoln Park Capital

CAMBRIDGE, Mass., March 20, 2020 (GLOBE NEWSWIRE) -- Unum Therapeutics Inc. (NASDAQ: UMRX), a biopharmaceutical company focused on developing curative cell therapies for solid tumors, today announced it has entered into a common stock purchase agreement for up to $25 million with Lincoln Park Capi…
Show more

UNUM Therapeutics Blogs

Cogent Biosciences Provides Corporate Updates and Reports First Quarter 2021 Financial Results

Cogent Biosciences Provides Corporate Updates and Reports First Quarter 2021 Financial Results Content Import Wed, 05/12/2021 - 07:03 Cogent Biosciences Provides Corporate Updates and Reports First Quarter 2021 Financial Results May 12, 2021 at 7:00 AM EDT Thi…

Cogent Biosciences Announces Creation of Cogent Research Team

Names industry veteran John Robinson, PhD as Chief Scientific Officer New Boulder-based team with exceptional track record of drug discovery and development focused on creating novel small molecule therapies for rare, genetically driven diseases Strong year-end cash position of $242.2 million

Cogent Biosciences Reports Fourth Quarter 2020 and Full Year 2020 Financial Results

CGT9486 clinical trial initiations on-track: Advanced Systemic Mastocytosis (1H21), Non-Advanced Systemic Mastocytosis (2H21), Gastrointestinal Stromal Tumors (GIST) (2H21) Final data from CGT9486 + sunitinib Phase 1/2 study presented at CTOS 2020 demonstrated 12 months median PFS and 20% ORR,

Cogent Biosciences Appoints Accomplished Finance Executive Todd E. Shegog to its Board of Directors

Cogent Biosciences Appoints Accomplished Finance Executive Todd E. Shegog to its Board of Directors Content Import Mon, 02/22/2021 - 07:02 Cogent Biosciences Appoints Accomplished Finance Executive Todd E. Shegog to its Board of Directors February 22, 2021 at 7:00 AM EST …

Cogent Biosciences to Present at Virtual 10th Annual SVB Leerlink Global Healthcare Conference 2021

Cogent Biosciences to Present at Virtual 10th Annual SVB Leerlink Global Healthcare Conference 2021 Content Import Thu, 02/18/2021 - 07:02 Cogent Biosciences to Present at Virtual 10th Annual SVB Leerlink Global Healthcare Conference 2021 February 18, 2021 at 7:00 AM EST …

Cogent Biosciences to Present at LifeSci Partners Virtual Precision Oncology Day 2021

CAMBRIDGE, Mass. , Feb. 11, 2021 /PRNewswire/ -- Cogent Biosciences , Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced that Andrew Robbins , Chief Executive Officer and President, will present a corporate
Show more

UNUM Therapeutics Frequently Asked Questions

  • When was UNUM Therapeutics founded?

    UNUM Therapeutics was founded in 2014.

  • Who are UNUM Therapeutics key executives?

    UNUM Therapeutics's key executives are John Green, Erin Schellhammer and Peter Harwin.

  • How many employees does UNUM Therapeutics have?

    UNUM Therapeutics has 56 employees.

  • What is UNUM Therapeutics revenue?

    Latest UNUM Therapeutics annual revenue is $8.4 m.

  • What is UNUM Therapeutics revenue per employee?

    Latest UNUM Therapeutics revenue per employee is $149.3 k.

  • Who are UNUM Therapeutics competitors?

    Competitors of UNUM Therapeutics include Silk Technologies, Microskin and NovellusDx.

  • Where is UNUM Therapeutics headquarters?

    UNUM Therapeutics headquarters is located at 200 Cambridgepark Dr #3100, Cambridge.

  • Where are UNUM Therapeutics offices?

    UNUM Therapeutics has an office in Cambridge.

  • How many offices does UNUM Therapeutics have?

    UNUM Therapeutics has 1 office.